The Journal of Headache and Pain, 2020 Background erenumab was safe and effective in clinical trials for the prevention of migraine. However, real-life data are still lacking. Here we report the clinical experience from an Italian real-world setting using erenumab in patients with chronic ...
Antonio Russo +7 more
doaj +1 more source
Predictors of clinical response to erenumab in patients with migraine
Cephalalgia Reports, 2022 Background: Anti-CGRP monoclonal antibodies have emerged as efficacious preventive therapies for some, but not all patients with migraine. It is not yet fully understood what predicts treatment response.
Olga Lekontseva +2 more
doaj +1 more source
Does erenumab reduce monthly migraine frequency from baseline in adults with episodic migraines? [PDF]
, 2023 OBJECTIVE: The objective of this selective EBM review is to determine “Does erenumab reduce monthly migraine frequency from baseline in adults with episodic migraines?” STUDY DESIGN: An EBM review of three double blind, RCTs (randomized control trials ...
Pitman, Rachel M.
core +1 more source
Anti-CGRP monoclonal antibodies in chronic migraine with medication overuse: real-life effectiveness and predictors of response at 6 months [PDF]
, 2021 Erenumab; Migranya; Anticossos monoclonalsErenumab; Migraña; Anticuerpos monoclonicosErenumab; Migraine; Monoclonal antibodiesBackground In daily practice, anti-CGRP monoclonal antibodies (MAbs) may be useful in chronic migraine (CM) with medication ...
Alpuente, Alicia +5 more
core +2 more sources
Erenumab in chronic migraine: Patient-reported outcomes in a randomized double-blind study. [PDF]
, 2019 OBJECTIVE: To determine the effect of erenumab, a human monoclonal antibody targeting the calcitonin gene-related peptide receptor, on health-related quality of life (HRQoL), headache impact, and disability in patients with chronic migraine (CM). METHODS:
Cheng, Sunfa +10 more
core +1 more source
Did the French pregnancy pictogram change antiseizure medication use during pregnancy?
Epilepsia, EarlyView.Abstract Objective The aim of this study was to assess the impact of introducing a pregnancy pictogram on medication packaging on the prescription and dispensation of antiseizure medications and on the maternal and neonatal outcomes for women exposed to these medications.
Mélanie Araujo +7 more
wiley +1 more source
Novel approaches for drug development against chronic primary pain: A systematic review
British Journal of Pharmacology, EarlyView.Abstract Chronic primary pain (CPP) persisting for more than 3 months, associated with significant emotional distress without any known underlying cause, is an unmet medical need. Traditional or adjuvant analgesics do not provide satisfactory pain relief for a great proportion of these patients.
Valéria Tékus +5 more
wiley +1 more source
Effectiveness and acceptability of oral migraine preventives: A prospective, observational study
Headache: The Journal of Head and Face Pain, EarlyView.Abstract Objective To explore the adherence, effectiveness, safety, tolerability, and acceptability of frequently used oral migraine preventive drugs in a real‐world setting. Background Oral migraine preventives are previously mainly explored in randomized controlled trials, whereas real‐world data on treatment outcomes remain limited. Methods MigriNor
Hedda S. Riise +13 more
wiley +1 more source
Neurology and Therapy, 2023 Introduction Erenumab, a fully human monoclonal antibody against the calcitonin gene-related peptide receptor, is approved in Japan for the prevention of adult migraine.
Shigekazu Kitamura +8 more
doaj +1 more source
Comparative Study of the Efficacy of Anti-CGRP mAbs on Migraineurs: Analysis of the First Year of Therapy, 1-Month Suspension Period, and Reprisal [PDF]
, 2023 : Background: Few studies compare the clinical effectiveness of the three anti-CGRP mAbs. Moreover, no studies compare their efficacy during suspension and reprisal.
Belgrado, Enrico +13 more
core +1 more source